Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy.

Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma.

Dr. Neeha Zaidi is a physician scientist and a medical oncologist, caring for patients with pancreatic and colorectal cancers. Dr. Zaidi received her undergraduate degree (Magna Cum Laude) in Biology from Cornell University and earned her M.D. from the Mount Sinai School of Medicine where she graduated with Distinction in Research. During medical school, she spent a year as a Howard Hughes Medical Institute (HHMI) Research Fellow at The Rockefeller University studying dendritic cell vaccines. She completed her residency in internal medicine at Weill Cornell and subsequently received an Intramural Research Training Award to perform a year-long post-doctoral fellowship at the Vaccine Research Center (NIAID) at the NIH. She then completed a fellowship in medical oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Zaidi joined the Johns Hopkins faculty in 2019. Dr. Zaidi’s laboratory focuses on developing novel personalized immunotherapy approaches for the treatment and prevention of pancreatic cancer. Dr. Zaidi has most recently been recognized with an ASCO Career Development Award and a NCI K08 Award. Dr. Zaidi is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, and Fibrolamellar Carcinoma.

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

Dr. Stefan Loy Zimmerman is a Professor in the Johns Hopkins University School of Medicine in the Departments of Radiology and Medicine (Cardiology). He specializes in cardiothoracic imaging and is the Division Director of Diagnostic Imaging and Director of Cardiac Imaging. He is the program director for the Cardiothoracic Imaging Fellowship in Radiology. Dr. Zimmerman earned his medical degree from the University of Pennsylvania School of Medicine. He completed both a radiology residency and a cardiovascular imaging fellowship at the Hospital of the University of Pennsylvania. His research focuses on the use of CT and MR imaging in the diagnosis and management of cardiovascular diseases. He has particular interest in the use of cardiac imaging for management of arrhythmias, diagnosis and prognosis of arrhythmogenic right and left ventricular cardiomyopathy, and pulmonary hypertension. Dr. Zimmerman is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Paroxysmal Supraventricular Tachycardia (PSVT), Alveolar Soft Part Sarcoma, Liposarcoma, Cardiac Ablation, and Transcatheter Aortic Valve Replacement (TAVR).

Dr. Julianna Czum’s primary focus is cardiothoracic imaging, with clinical subspecialties in noninvasive cardiovascular and thoracic imaging. Dr. Czum earned her medical degree from UMDNJ - Robert Wood Johnson Medical School before going on to an internship at Mary Imogene Bassett Hospital and residency at St. Barnabas Medical Center. She completed a fellowship in cardiovascular magnetic resonance in a combined Henry Jackson Foundation-funded program at the National Institutes of Health, National Naval Medical Center and Uniformed Services University of the Health Sciences. Dr. Czum joined the diagnostic faculty in June 2022. Dr. Czum is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Pleurisy, ALK-Positive Non-Small Cell Lung Cancer, Chronic Cough, and Lung Nodules.

As a member of the Johns Hopkins Kimmel Cancer Center, my group's research is focused on finding novel therapies for the treatment of both acute and chronic graft versus host disease (GVHD). To that end, we are developing new strategies for prophylaxis as well as therapies for this problem. We are exploring the use of drugs such as pentostatin in steroid refractory GVHD. This drug inhibits an enzyme, called ADA, that induces apoptosis (cell death) of lymphocytes, the effector cells in GVHD. Our results using this approach have been quite encouraging. Also, we are exploring other novel approaches such as extracorporeal photopheresis or high-dose cyclophosphamide. We are participating in the NIH Bone Marrow Transplant Clinical Trials Network consortium to find useful therapies for GVHD. We are also members of the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials on Chronic GVHD, and there we are trying to establish rational guidelines for supportive care, trial design, etc. We run an internationally unique GVHD multidisciplinary clinic with many GVHD experts including a nurse practitioner, research nurse and others from fields such as physical medicine and rehabilitation, gastroenterology, ophthalmology, dermatology, pulmonology and more. Dr. Meade is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Multiple Myeloma, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

Panayotis Ledakis is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Ledakis is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy. Dr. Ledakis is currently accepting new patients.

Seung Lee is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Christopher Melani is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Melani is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Lymphomatoid Granulomatosis, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

Nagina Malguria is a Radiologist in Baltimore, Maryland. Dr. Malguria is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Fibrosing Mediastinitis, Neuroendocrine Tumor, Lung Nodules, and Pleural Effusion.

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

Rosemary Olivo is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Olivo is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Breast Cancer, Type 2 Diabetes (T2D), Hemoglobin SC Disease, and Maturity Onset Diabetes of the Young.